PMID: 9192661Jun 24, 1997Paper

Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity

Proceedings of the National Academy of Sciences of the United States of America
T D ArmstrongS Ostrand-Rosenberg

Abstract

We have developed an immunotherapy in which tumor cells transfected with syngeneic major histocompatibility complex (MHC) class II genes are cell-based vaccines for the treatment of established tumor and metastatic disease. If this strategy is to be used clinically, convenient methods for generating class II+ tumor cells are necessary. Interferon-gamma treatment or transduction of the class II transactivator (CIITA) gene induces class II expression but also up-regulates the class II-associated accessory molecules, invariant chain (Ii) and DM. To determine if interferon-gamma treatment and CIITA transduction are potential immunotherapies, we assessed the tumorigenicity of sarcoma cells expressing combinations of class II, Ii, and DM. Since we hypothesized that class II-transfected tumor cells not coexpressing Ii and DM present endogenously encoded tumor peptides, we have assessed the transfectants for antigen presentation activity to MHC class II-restricted antigen-specific CD4(+) T cells. Tumor challenge studies demonstrate that tumor cells expressing class II without coexpression of Ii or Ii plus DM are highly immunogenic and preferentially present endogenous antigens, while tumors coexpressing class II with Ii or Ii plus DM a...Continue Reading

References

Oct 1, 1992·Current Opinion in Immunology·D Pardoll
Nov 1, 1986·The Journal of Experimental Medicine·J Miller, R N Germain
Jun 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·S BaskarL H Glimcher
Oct 1, 1994·Current Opinion in Immunology·S Ostrand-Rosenberg
Feb 1, 1995·The Journal of Experimental Medicine·C H Chang, R A Flavell
Apr 1, 1995·Scandinavian Journal of Immunology·T CabreraF Garrido
Jan 1, 1994·Annual Review of Immunology·T BoonA Van Pel
Jan 1, 1993·Annual Review of Immunology·R N Germain, D H Margulies
May 14, 1993·Science·R C Mulligan
Dec 5, 1995·Proceedings of the National Academy of Sciences of the United States of America·T C WuD M Pardoll
Jan 1, 1996·Annual Review of Immunology·B MachW Reith
Oct 1, 1996·Current Opinion in Immunology·P F Robbins, Y Kawakami
Oct 1, 1996·Current Opinion in Immunology·D M Pardoll
Dec 24, 1996·Proceedings of the National Academy of Sciences of the United States of America·G J NabelA E Chang
Apr 1, 1985·Immunology Today·G Trinchieri, B Perussia

❮ Previous
Next ❯

Citations

Feb 28, 1998·Immunologic Research·M S Marks
Aug 29, 2007·Cancer Immunology, Immunotherapy : CII·James A ThompsonSuzanne Ostrand-Rosenberg
Aug 23, 2000·Immunology Today·B SeligerS Ferrone
Mar 31, 2000·Trends in Biotechnology·M XuR E Humphreys
Jan 16, 1998·Immunology and Cell Biology·D M MahviN S Yang
Mar 29, 2002·Immunology·John H Robinson, Alexei A Delvig
Jul 6, 2001·Scandinavian Journal of Immunology·N SetterbladN Mooney
Apr 12, 2000·International Journal of Dermatology·M T LinK Yoon
Oct 3, 2008·International Immunology·Andrea De Lerma BarbaroRoberto S Accolla
Jun 6, 2000·Journal of Immunotherapy·M S BradyJ S Lee
Jan 13, 2000·Immunological Reviews·J van BergenF Koning
Aug 11, 2000·Molecular and Cellular Biology·J A Harton, J P Ting
Feb 18, 2009·BMC Immunology·Diana P GranadosClaude Perreault
Jul 20, 2010·Immunotherapy·Marvin M van LuijnArjan A van de Loosdrecht
Apr 6, 2011·Experimental & Molecular Medicine·Yeong Shin LeeChul Woo Kim
Oct 11, 2012·Revista brasileira de hematologia e hemoterapia·Daiana Landenberger de CarvalhoSandra Trevisan Beck
Jun 25, 2008·International Immunopharmacology·Hongyan GuXiaotang Wang
Nov 10, 2010·The Breast Journal·Roberto S AccollaLorenzo Mortara
Aug 22, 2006·Immunobiology·M E D ChamuleauA A van de Loosdrecht
Aug 19, 2015·Molecular Immunology·Nathaniel H BoydSusanna F Greer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.